HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
Clinical Trial: Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Posted: Aug 10, 2017
Clinical Trial: Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma image
 Daratumumab is a newer immunotherapy approved by the FDA for relapsed myeloma. Because it has few side effects, many researchers want to see if it can be used in precursor stages of the disease to prevent it from progressing to active myeloma. 

This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is Daratumumab.

The trial is open at the Dana Farber Cancer Institute, run by Dr. Irene Ghobrial, a myeloma specialist with a focus on precursor conditions. It is also open at Beth Israel Deaconess Medical Center in Boston.

To learn more about this trial and sign up to receive notifications, click here:  Study of the CD38 Antibody Daratumumab Clinical Trial

To find all eligible clinical trials, click here: 

Study of the CD38 Antibody Daratumumab Clinical Trial
The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Amgen Oncology
Abbvie
Genentech
GSK
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube